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Background: Activation of the insulin-like growth factor 1 (IGF-1) pathway is involved in cell 
growth and proliferation and is associated with tumorigenesis, tumor progression, and therapy 
resistance in solid tumors. We examined whether variability in serum levels of IGF-1, IGF-2, 
and IGF-binding protein 3 (IGF-BP3) can predict event-free survival (EFS) and overall survival 
(OS) in Ewing sarcoma patients treated with chemotherapy.
Patients and methods: Serum levels of IGF-1, IGF-2, and IGF-BP3 of 22 patients with 
localized or metastasized Ewing sarcoma treated with six cycles of vincristine/ifosfamide/
doxorubicin/etoposide (VIDE) chemotherapy were recorded. Baseline levels were compared 
with presixth cycle levels using paired t-tests and were tested for associations with EFS and OS. 
Continuous variables were dichotomized according to the Contal and O’Quigley procedure. 
Survival analyses were performed using Cox regression analysis.
Results: High baseline IGF-1 and IGF-BP3 serum levels were associated with EFS (hazard ratio 
[HR] 0.075, 95% confidence interval [CI] 0.009–0.602 and HR 0.090, 95% CI 0.011–0.712, 
respectively) in univariate and multivariate analyses (HR 0.063, 95% CI 0.007–0.590 and HR 
0.057, 95% CI 0.005–0.585, respectively). OS was improved, but this was not statistically sig-
nificant. IGF-BP3 and IGF-2 serum levels increased during treatment with VIDE chemotherapy 
(P=0.055 and P=0.023, respectively).
Conclusion: High circulating serum levels of IGF-1 and IGF-BP3 and the molar ratio of 
IGF-1:IGF-BP3 serum levels were associated with improved EFS and a trend for improved 
OS in Ewing sarcoma patients treated with VIDE chemotherapy. These findings suggest the 
need for further investigation of the IGF-1 pathway as a biomarker of disease progression in 
patients with Ewing sarcoma.
Keywords: Ewing sarcoma, chemotherapy, IGF-1, IGF-2, IGF-BP3, IGF-1R, survival, 
biomarkers
Introduction
Ewing sarcoma is a rare form of cancer; however, it is the second most common 
bone sarcoma in children and young adults. The disease is usually primarily localized 
in the skeleton but may occur in soft tissue. Mortality is high despite intensive 
multidisciplinary treatment, including surgery, chemotherapy, and radiotherapy:1 
overall survival (OS) at 5 years is 30% in patients with primary metastatic disease 
and 60% in patients with localized disease.2 Evidence suggests that the insulin-like 
growth factor 1 (IGF-1) pathway plays a major role in the pathogenesis of Ewing 
sarcoma.3,4 The IGF-1 pathway consists of the IGF-1 receptor (IGF-1R), two ligands 
(IGF-1 and IGF-2), and six IGF-binding proteins (IGF-BP1-6), of which IGF-BP3 
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is the most abundant.5–7 The insulin receptor (IR) is highly 
homologous to the IGF-1R, allowing for the formation of 
hybrid receptors that can activate the downstream pathway. 
The A isoform of the IR, which is predominant in cancer 
cells, can also activate the pathway.6,8
Eighty-five percent of Ewing sarcoma tumors are marked 
by the chromosomal translocation t(11;22).9 This somatic 
mutation results in aberrant products of the Ewing sarcoma 
breakpoint region 1 (EWSR1) and the Friend leukemia virus 
integration 1 (FLI1) genes. The EWSR1-FLI1 oncoprotein 
binds to the IGFBP3 promoter, which inhibits expression 
of IGF-BP3 (Figure 1).3,4 The biological activity of IGF-1 is 
inhibited primarily by binding IGF-BP3.5,10 Therefore, high 
levels of bioavailable IGF-1 (and IGF-2) may activate the 
IGF-1R in Ewing sarcoma to stimulate Ras/MAPK and PI3K/
AKT pathways, through which cell proliferation is promoted 
and apoptosis inhibited.5,8
Convincing preclinical evidence of the efficacy of 
IGF-1 pathway inhibitors in the context of cancer treatment 
has led to the development of numerous such agents that 
have been investigated in clinical trials as treatments for 
Ewing sarcoma, breast cancer, and other solid tumors.6,11–13 
Unfortunately, convincing clinical benefits of these agents 
have been limited to rare long-lasting effects in a small 
proportion of patients with Ewing sarcoma.13 A better under-
standing of the role of the IGF-1 pathway could therefore 
help illuminate specific therapeutic targets and potential 
biomarkers of disease progression.
This observational study examined whether circulating 
levels of IGF-1 pathway components predict the (event-free) 
survival of Ewing sarcoma patients treated with vincristine/
ifosfamide/doxorubicin/etoposide (VIDE) chemotherapy.
Patients and methods
study population
Patients with primary localized or metastatic Ewing sarcoma 
who were treated between 2009 and 2014 with VIDE che-
motherapy (1.5 mg/m2 of vincristine on day 1, 3,000 mg/m2 
of ifosfamide on days 1/2/3, 20 mg/m2 of doxorubicin on 
days 1/2/3, and 150 mg/m2 of etoposide on days 1/2/3) at the 
Department of Medical Oncology, Leiden University Medical 
Center, were included. For all participants, the diagnosis was 
established in a multidisciplinary setting and confirmed using 
molecular analysis. Response of the tumor to chemotherapy 
was defined according to the Van der Woude classification 
as “good” or “poor”, based on pathology and/or radiology 
reports, where available.14,15 The study was conducted accord-
ing the Dutch “Code of Good Conduct” and was approved 
by the ethics committee of the Leiden University Medical 
Center. Patient consent was assumed as per the no-objection 
rule of the Code of Good Conduct (https://www.federa.
org/codes-conduct). Biomarker data have been reported in 
accordance with REMARK criteria.16
Blood sampling and assay methods
Fasting blood samples were obtained immediately prior to 
the first and sixth chemotherapy cycles. Serum levels of 
IGF-1 (IDS-iSYS; Immunodiagnostic Systems, Frankfurt, 
Germany) and IGF-BP3 (Immulite 2500; Siemens, The 
Hague, the Netherlands) were analyzed by chemilumines-
cence immunoassay (CIA). The IGF-1 assay is traceable to 
the WHO IS 02/254.17 The IGF-BP3 assay is traceable to 
WHO NIBSC Reagent 93/560 according to IFU: IMMULITE 
2000 IGF-BP3 (PIL2KGB-14, 2012-06-18).18 Serum IGF-2 
was analyzed by radioimmunoassay after Sep-Pak C18 
column extraction calibrated to WHO 96/538 international 
standard.19
statistical analysis methods
The primary outcome measure was the association of baseline 
serum levels of IGF-1, IGF-2, and IGF-BP3 with event-free 
survival (EFS). Secondary outcome measures included the 
association of baseline serum levels of IGF-1, IGF-2, and 
IGF-BP3 with presixth cycle levels and with OS.
Figure 1 schematic overview of the effect of eWsr1-Fli1oncoprotein on igF-1 
pathway in ewing sarcoma cells.
Note: eWsr1-Fli1 binds the promoter region of igF-BP3, which inhibits 
transcription.
Abbreviations: eWsr1-Fli1, ewing sarcoma breakpoint region 1-Friend leukemia 
virus integration 1; igF-1, insulin-like growth factor 1; igF-BP3, insulin-like growth 
factor-binding protein 3; igF-2, insulin-like growth factor 2; igF-1r, insulin-like 
growth factor 1 receptor; ir-a, insulin receptor isoform a; Pi3K, phosphatidylinositol- 
3-kinase; aKT, protein kinase B; MaPK, mitogen-activated protein kinase.
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A linear regression model was used to study the association 
between age and IGF-1. Mean serum levels were compared 
using a t-test for paired groups. To dichotomize continuous 
covariates for use in a Cox model, the Contal, and O’Quigley 
technique based on the log-rank test statistic was used. This 
method cutoff point for the covariate of interest at which the 
largest difference is seen between individuals in two groups. 
The procedure involves estimation of the cutoff point for the 
covariate and tests the hypothesis that this covariate in its 
binary version has no effect on the outcome. Technical details 
concerning the procedure are described elsewhere.20,21 In this 
study, the median was used as the cutoff point for IGF-BP3 
serum levels. Since there were no events in one of the groups 
identified by using the Contal and O’Quigley procedure, a Cox 
model could not be performed. EFS was defined as time from 
date of diagnosis until the date of the earliest documented 
disease recurrence or progression or death from any cause. 
OS was defined as time from date of diagnosis until date 
of death from any cause. Median follow-up was calculated 
by applying the reverse Kaplan–Meier methodology.22 Cox 
regression models were used to evaluate the effect of the 
covariates on EFS and OS. Hazard ratios (HRs) and 95% 
confidence intervals (95% CIs) were calculated. Serum levels 
of the components of the IGF-1 pathway that were found to 
be significant (to 1%) in univariate Cox regression models 
were carried forward to the multivariate model. Relevant risk 
factors described in the literature or found to have a P-value 
of less than 0.1 in univariate analyses were incorporated in 
the multivariate model. All tests were two tailed. P-values 
of less than 0.05 were considered significant. All data were 
analyzed using Statistical Package for Social Sciences 
(SPSS) software™ 20.0 (IBM Corp., Armonk, NY, USA) 
and R version 3.3 (R Foundation for Statistical Computing, 
Vienna, Austria).23
Results
Patient characteristics
The clinical characteristics at diagnosis of the 22 Ewing 
sarcoma patients included in the study are shown in Table 1. 
All patients were 16 years or older. Nine patients had metas-
tastic disease and 13 had localized disease at initial diagnosis. 
One patient received two cycles of etoposide and cisplatin 
chemotherapy before the diagnosis of Ewing sarcoma was 
made as small-cell carcinoma was initially suspected. Three 
patients were diagnosed with Ewing sarcoma only after 
surgical excision of the tumor. Two of those patients were 
diagnosed with an incidental extraskeletal Ewing sarcoma of 
the kidney and one patient of the adrenal gland.
igF pathway serum levels during chemotherapy
Serum samples at baseline and after five VIDE cycles 
were available for 22 and 13 patients, respectively. For 
nine patients, no samples were collected due to logistical 
reasons. There was no significant difference in IGF-1 serum 
levels in patients with metastastic disease versus localized 
disease (mean values 28.2 versus 34.4 nmol/L [P=0.227], 
respectively). At baseline, age was significantly associated 
with IGF-1 values (P=0.035) in our cohort. Baseline IGF-1, 
IGF-2, and IGF-BP3 levels were compared with levels prior 
to the sixth chemotherapy cycle. IGF-1 levels did not change 
significantly during chemotherapy. IGF-BP3 and IGF-2 
levels increased during chemotherapy (P=0.055 and P=0.023, 
respectively). Mean values of IGF-1, IGF-2, and IGF-BP3 
at baseline and presixth cycle are shown in Figure 2. IGF-1, 
IGF-BP3, and IGF-2 levels in subjects with good response 
and poor response were compared according to the Van 
der Woude classification using data from pathology and/
or radiology reports. Three patients underwent surgery 
before diagnosis, so it was not possible to assess response 
to chemotherapy. Fourteen patients showed a good response 
Table 1 Patient characteristics
Patients (N=22)
gender
Female 6 (27.3%)
Male 16 (72.7%)
age (years)
range 16–62
,18 3 (13.6%)
$18–30 10 (45.5%)
$30 9 (40.9%)
Median BMi (range), kg/m2 22.7 (17.0–36.8)
chemotherapy before diagnosis
Yes 1 (4.5%)
no 21 (95.5%)
surgery before diagnosis
Yes 3 (13.6%)
no 19 (86.4%)
extraskeletal
Yes 5 (22.7%)
no 17 (77.3%)
Metastasis
With metastasis 9 (40.9%)
Only pulmonary 4 (18.2%)
skeletal 3 (13.6%)
Bone marrow 2 (9.1%)
Without metastasis 13 (59.1%)
response to chemotherapy
good 14 (63.6%)
Poor 5 (22.7%)
not applicable 3 (13.6%)
Abbreviation: BMi, body mass index.
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and five patients a poor response to chemotherapy. IGF-1, 
IGF-BP3, and IGF-2 levels at baseline were not associated 
with response to chemotherapy (P=0.702, P=0.912, and 
P=0.888, respectively).
serum levels and association with survival
The median follow-up was 3.25 years (95% CI 2.25–4.25). 
For baseline values of IGF-1 and IGF-2 and the molar IGF-1: 
IGF-BP3 ratio, the cutoff point based on the Contal and 
O’Quigley procedure was equal to 28.7 nmol/L, 608 ng/mL 
and 0.21, respectively. The median cutoff point of baseline 
values of IGF-BP3 was 4.7 mg/L. Kaplan–Meier curves for 
IGF-1, IGF-2, IGF-BP3, the molar IGF-1:IGF-BP3 ratio, 
and the number of patients per group are shown in Figure 3. 
In this analysis, IGF-1, IGF-BP3, and the molar IGF-1:IGF-
BP3 ratio are prognostic factors for survival. Risk factors 
described in the literature to be associated with survival24 and 
those with P,0.1 in univariate analyses were included in the 
regression model for multivariate analysis. A Cox model was 
used to study the association between risk factors and survival 
outcomes. The estimated HRs and associated 95% confidence 
intervals for univariate and multivariate analyses are shown 
in Table 2. Age and body mass index (BMI) were adjusted 
for in the multivariate Cox model. IGF-1 was a significant 
prognostic factor for EFS (HR 0.063, 95% CI 0.007–0.590, 
P=0.015). This was not a significant for OS in this patient 
group (HR 0.162, 95% CI 0.017–1.496, P=0.109). IGF-BP3 
was significantly associated with EFS (HR 0.057, 95% CI 
0.005–0.585, P=0.016), but not OS (HR 0.125, 95% CI 
0.011–1.423, P=0.094). IGF-2 levels were not significantly 
associated with EFS (HR 1.064, 95% CI 0.164–6.905, 
P=0.948) or OS (HR 5.297, 95% CI 0.451–62.24, P=0.185) 
(not shown). To investigate the influence of free IGF-1, 
the molar IGF-1:IGF-BP3 ratio was used as risk factor. 
The molar IGF-1:IGF-BP3 ratio was associated with EFS 
(HR 0.103, 95% CI 0.011–0.934, P=0.043), but not OS 
(HR 0.163, 95% CI 0.017–1.546, P=0.225) in multivariate 
analyses. IGF-1, IGF-BP3, and IGF-2 serum alterations were 
not associated with EFS or OS.
IGF-1 serum levels consistently decline after adolescence 
in healthy subjects.17 Therefore, levels were compared for each 
subject in our cohort to the age- and gender-matched reference 
value. The measured values were calculated as a percentage 
of the corresponding reference values. High percentage of 
measured IGF-1 compared to the reference value predicted 
EFS (HR 0.614 per 10% increase, 95% CI 0.405–0.931, 
P=0.021), but not OS (HR 0.703 per 10% increase, 95% CI 
0.460–1.075, P=0.104) in multivariate analysis.
Discussion
We found that high baseline IGF-1 and IGF-BP3 serum levels 
and the molar IGF-1:IGF-BP3 ratio in serum were associated 
with improved EFS and a trend for OS in Ewing sarcoma 
patients treated with VIDE chemotherapy. IGF-2 serum 
levels were not significantly associated with EFS or OS. 
Moreover, IGF-BP3 and IGF-2 serum levels increased during 
VIDE chemotherapy in this patient group. IGF-1 serum levels 
did not change during chemotherapy.
It seems counterintuitive that high levels of IGF-1 predict 
better survival in Ewing sarcoma, as IGF-1 is involved in the 
development, progression and therapy resistance of several 
solid tumors.7 However, low levels of IGF-1 may reflect 
Figure 2 Serum levels of IGF-1, IGF-BP3, and IGF-2 at baseline and after five cycles of VIDE chemotherapy (N=13).
Abbreviations: igF-1, insulin-like growth factor 1; igF-BP3, insulin-like growth factor binding protein 3; igF-2, insulin-like growth factor 2; ViDe, vincristine/ifosfamide/
doxorubicin/etoposide; CI, confidence interval.
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Figure 3 Kaplan–Meier curves of event-free survival (left column) and overall survival (right column) for igF-1, igF-BP3, and molar igF-1 (nm/l):igF-BP3 (nm/l) ratio levels 
under or above the cutoff point.
Note: P-values are given for the univariate analyses of the cox regression analyses.
Abbreviations: igF-1, insulin-like growth factor 1; igF-BP3, insulin-like growth factor-binding protein 3; eFs, event-free survival; Os, overall survival.
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an endocrine adaptation to (severe) disease.25 Indeed, low 
levels of IGF-1 were reported to be associated with greater 
tumor burden and more aggressive systemic illness in Ewing 
sarcoma.26 Additionally, lower levels of IGF-1 were reported 
in five patients with metastatic disease compared to patients 
with localized disease.26 Toretsky et al27 also reported that 
Ewing sarcoma patients with metastatic disease had lower 
circulating IGF-1 levels than patients with localized dis-
ease, suggesting that more severe illness downregulates 
IGF-1 production in the liver. In keeping with these reports, 
we observed lower levels of serum IGF-1 in patients with 
metastatic disease compared to localized disease, but the 
difference was not statistically significant, perhaps because 
of the small population size. Interestingly, low levels of 
circulating IGF-1 predicted worse survival in other solid 
tumors28–35 and systemic diseases.36,37 Borinstein et al38 did 
not find an association between serum IGF-1 levels and 
treatment outcome in 226 Ewing sarcoma patients, but this 
may be explained by the fact that relatively young patients 
were included compared to our study (88% of subjects were 
younger than 18 years), increasing the confounding effect of 
age-associated growth hormone and IGF-1 release.
In Ewing sarcoma, autocrine loops of IGF-1 signaling have 
been shown to be crucial for proliferation and cell survival 
in vitro.3,39–41 Indeed, serum IGF-1 levels may have little or 
no influence on tumor growth, as the autocrine production 
of IGF-1 (and IGF-2) is probably sufficient and decisive. 
Analogously, autocrine IGF-1 production by the tumor has 
been shown to be a negative predictor of survival in colorec-
tal cancer patients treated with cetuximab and irinotecan.42 
Presumably, autocrine IGF-1 production by the tumor does 
not affect circulating levels. Thus, we believe that circulating 
levels of IGF-related peptides reflect disease severity in various 
conditions, but cannot guide therapeutic strategies. In contrast, 
determining of autocrine IGF-1 (and IGF-2) levels and the 
expression of the IGF-1R in the tumor might help to select 
patients who could benefit from (co-)treatment with an IGF-1R 
inhibitor. Moreover, IGF-1R expression may be diminished 
after treatment with chemotherapy, which has been shown in 
breast cancer patients,43,44 suggesting that the efficacy of an 
IGF-1R inhibitor after chemotherapy might be diminished.
In our study, high IGF-BP3 serum levels predicted better 
EFS. IGF-BP3, the synthesis of which is primarily stimulated 
by growth hormone, inhibits the bioavailability of IGF-1 and 
has direct antitumor effects.8,45 In Ewing sarcoma cells, bind-
ing of the EWS-FLI oncoprotein to the IGF-BP3 promoter 
inhibits autocrine IGF-BP3 production.3,4 Therefore, perhaps 
high circulating levels of IGF-BP3 lead to better survival 
of Ewing sarcoma patients due to the direct apoptotic and 
growth inhibitory effects in Ewing sarcoma cells. Alterna-
tively, a decline of IGF-BP3 (along with IGF-1) may reflect 
an endocrine adaptation to severe disease.
We found that IGF-BP3 and IGF-2 serum levels increased 
during treatment with VIDE chemotherapy in Ewing sarcoma 
patients. Similarly, Kümmel et al46 observed that IGF-BP3 
serum levels increase during anthracycline and taxane chemo-
therapy in breast cancer patients, and Gallego et al34 reported 
that IGF-BP3 serum levels increase during FOLFOX (Folinic 
acid, Fluorouracil and Oxaliplatin) or FOLFIRI (Folinic acid, 
Fluorouracil and Irinotecan) chemotherapy in colorectal can-
cer. Interestingly, in the latter study, IGF-BP3 serum levels 
increased when the tumor was stable or responding to therapy 
but declined upon disease progression.34 Although IGF-2 is 
three times more abundant in serum than IGF-1, our under-
standing of this protein is limited,47 but it is possible that the 
increase in serum IGF-BP3 and IGF-2 levels during treatment 
is a systemic reflection of (partial) disease recovery.
The sample size of our study is small, and the results 
clearly need validation in a larger cohort. However, our 
data suggest that high circulating levels of IGF-1 pathway 
components predict longer EFS in patients with Ewing sar-
coma treated with VIDE chemotherapy. This observation 
Table 2 Univariate and multivariate cox models of eFs for igF-1, igF-BP3, igF-2, and igF-1:igF-BP3
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Metastasis at diagnosis 2.061 0.575–7.380 0.267
age 1.021 0.973–1.071 0.396
BMi 1.158 0.998–1.343 0.053
igF-1 0.075 0.009–0.602 0.015 0.063 0.007–0.590 0.015
igF-BP3 0.090 0.011–0.712 0.022 0.057 0.005–0.585 0.016
igF-2 1.809 0.451–7.254 0.403
igF-1:igF-BP3 0.082 0.010–0.660 0.019 0.103 0.011–0.934 0.043
Note: Bold values indicate P,0.05.
Abbreviations: eFs, event-free survival; hr, hazard ratio; igF-1, insulin-like growth factor 1; igF-BP3, insulin-like growth factor-binding protein 3; igF-2, insulin-like growth 
factor 2; HR, hazard ratio; CI, confidence interval; BMI, body mass index.
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igF-1 predicts ewing sarcoma survival
apparently contrasts with data showing that autocrine produc-
tion of IGF-1 by tumor tissue promotes tumor growth.5,8,47 
A possible unifying explanation is that perhaps low 
circulating levels of the IGF-1 pathway components reflect 
an endocrine response to severe disease in contrast to the 
autocrine production of IGF-1 by tumor tissue that primarily 
determines tumor growth.34,48 This theory is consistent with 
findings, including those of this study, of increased circulat-
ing IGF-BP3/IGF-2 levels in the course of chemotherapy for 
various tumor types.34,46
Conclusion
High circulating levels of IGF-1 and IGF-BP3 at baseline 
appear to be a favorable indicator of outcome in Ewing 
sarcoma patients treated with chemotherapy. These findings 
suggest the need for further investigation of the value of the 
IGF-1 pathway as biomarker for treatment outcome and 
treatment target in Ewing sarcoma.
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